• Contact Us

    News

    • Plant 3

      OSD and Injectable Oncology - Verna, Goa - Installation completed and under process validation

      2019-04-08 14:55:31

    • Plant 2

      OSD - Skidel, Belarus Inaugurated on 7-Mar-19. Commercial Licence Obtained in Dec-2019

      2020-01-25 10:12:34

    • Plant 4

      ONCO API, Goa - Building is ready, machine installations in progress

      2019-09-24 17:49:06

    • Fight against Covid-19

      Face mask, Two Yard distance and hand wash is must

      2020-10-16 14:21:39

    • DSIR Approved R&D Centre

      R&D and ADL centre has certified by DSIR, Govt. of India.

      2020-10-16 14:22:49

    Quote

    • Launch of two products in our brand and for contract manufacturing Oseltamavir caps, 30mg, 45mg and 75 mg  And  Favipiravir 200 mg/400mg/800mg Tablet.

    Overview
     

    Past: Concept of backward integration from exporting to Manufacturing was conceived by Mr. Alok Kumar (Founder and Managing Director) in early millennium era when entire world was busy with Y2K issue. Lok-Beta commenced its activity in Apr-2002 from Mumbai, India with a range of Pharmaceutical and Healthcare products across globe along with plan to establish its own ultra modern manufacturing plant. First fully integrated Manufacturing Unit along with R&D centre operationalized supported by Warehouse as per GMP in 2008. First accreditations WHO-GMP, India received in Sep-2009. First overseas head quarter established in the heart of Moscow city, Russia in 2006.

    Present

    Lok-Beta is currently investing heavily in the research and development of new Pharmaceuticals & Healthcare formulations. The next few years will see a stream of new Lok-Beta products being established in the market Infrastructure:

    • Total area of constructed (RCC) factory is 4500 Sq.M
    • Tablets, Capsules, Liquid Suspension, Syrup, Ointment and Cream
    • GLP, FDA Maharashtra, India certified Laboratory, ISO 9001:2015  
    • WHO-GMP, PIC/s, Russian GMP and other international accreditation
    • Market : More than 32 countries in Asia, Africa and Latin America. At domestic front company has presence in 4 states.
    Way Forward
    • Skidel, Belarus plant – Oral dose Formulation & API . Manufacturing facility in 3rd quarter of 2018 (API in 3rd quarter of 2019)
    • GOA plant focusing on Oncology manufacturing – Sterile formulation with API non-sterile facility in 4th quarter of 2018
    • Annually 10 new products registration
    • EU approval (Pre qualification with EU GMP schedule in 2019)
    好吊操视频这里只有精品